WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2014202973) AGONISTS OF DDAH1 FOR TREATING ENDOTHELIAL DYSFUNCTION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2014/202973    International Application No.:    PCT/GB2014/051867
Publication Date: 24.12.2014 International Filing Date: 17.06.2014
IPC:
A61K 31/713 (2006.01), C12Q 1/68 (2006.01), C12N 15/113 (2010.01), A61P 9/10 (2006.01), A61P 9/12 (2006.01)
Applicants: UCL BUSINESS PLC [GB/GB]; The Network Building 97 Tottenham Court Road London W1T 4TP (GB)
Inventors: MOOKERJEE, Rajeshwar; (GB).
MEHTA, Gautam; (GB)
Agent: BENTHAM, Andrew; (GB)
Priority Data:
1310755.2 17.06.2013 GB
Title (EN) AGONISTS OF DDAH1 FOR TREATING ENDOTHELIAL DYSFUNCTION
(FR) AGONISTES DE DDAH1 UTILISÉS POUR LE TRAITEMENT D'UN DYSFONCTIONNEMENT ENDOTHÉLIAL
Abstract: front page image
(EN)The present invention derives from the finding that expression of DDAH1 is heavily post- transcriptionally regulated by microRNAs. By preventing or blocking the interaction between such microRNAs and the DDAH1 mRNA, the production of DDAH1 protein can be increased. This has utility in the prevention or treatment of diseases and disorders that are associated with reduced DDAH1 levels or increased ADMA levels, such as diseases or disorders that are characterised by endothelial dysfunction.
(FR)La présente invention est issue de la découverte selon laquelle l'expression de DDAH1 subit une forte régulation post-transcriptionnelle exercée par des micro-ARN (miARN). En empêchant ou en bloquant l'interaction entre de tels miARN et le miARN de DDAH1, la production de protéine DDAH-1 peut être augmentée. Ceci peut être utilisé dans la prévention ou le traitement de maladies et de troubles associés à des niveaux de DDAH1 réduits ou à des niveaux de ADMA augmentés, comme par exemple des maladies ou des troubles caractérisés par un dysfonctionnement endothélial.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)